Demeclocycline 是一种具有口服活性的四环素类抗生素，通过与 30S 核糖体亚单位结合来抑制氨基酰 tRNA 的结合，从而影响蛋白质的合成。Demeclocycline 对广谱的细菌感染表现出抗菌活性。
| 生物活性 | Demeclocycline is an orally activetetracyclineantibiotic. Demeclocycline impairs protein synthesis by binding to the 30S ribosomal subunit to inhibit binding of aminoacyl tRNA. Demeclocycline shows anti-bacterial activitise to a wide variety ofbacterialinfections[1][2]. |
| IC50& Target | |
体外研究
(In Vitro) | Demeclocycline (0-100 μM; 24 h) treatment reduces AQP2 abundance in mpkCCD cells[3].
Demeclocycline (10 μM; 24 h) treatment promotes the activity of monocytes and macrophages[4].
Demeclocycline (1-10 μM; 72 h) treatment directly affects the growth of brain tumorinitiating cells[4].
Western Blot Analysis[3] | Cell Line: | MpkCCD cells | | Concentration: | 0-100 μM | | Incubation Time: | 24 hours | | Result: | Decreased AQP2 abundance in mpkCCD cells, with significant effects at 50 μM. |
Cell Viability Assay[4] | Cell Line: | mouse bone marrow derived macrophages and monocytes | | Concentration: | 10 μM | | Incubation Time: | 24 hours | | Result: | Enhanced TNF-α production and modulated monocyte functions. |
Cell Viability Assay[4] | Cell Line: | brain tumorinitiating cells | | Concentration: | 1, 5, and 10 μM | | Incubation Time: | 72 hours | | Result: | Inhibited cells growth in two ways: using monocytes as an intermediary, and directly by affecting the proliferation and sphere-forming capacity of brain tumorinitiating cells. |
|
体内研究
(In Vivo) | Demeclocycline (Intraperitoneal injection; 40 mg/kg; once daily; 48 h) treatment results in a significant reduction of hyponatremia and a significant correction of the hypoosmolality, and is not nephrotoxic[3].
| Animal Model: | Male Wistar rats induced with hyponatremia[3] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; 40 mg/kg; once daily; 48 hours | | Result: | Increased urine volume, decreased urine osmolality, and caused a significantly increased fractional excretion of water. |
| Animal Model: | Male Wistar rats induced with hyponatremia[3] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; 40 mg/kg; once daily; 48 hours | | Result: | Indicated the effect in the renal inner medulla for AQP2 and AC5/6 specifically, and not secondary toxicity effect. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com